Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Leticia F. Tetteh
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, Leticia Tetteh wrote the following 2 articles about Melanoma.
 
+ Citations + Abstracts
1 Clinical Trial Combined BRAF and HSP90 Inhibition in Patients with Unresectable 2018

Eroglu, Zeynep / Chen, Y Ann / Gibney, Geoffrey T / Weber, Jeffrey S / Kudchadkar, Ragini R / Khushalani, Nikhil I / Markowitz, Joseph / Brohl, Andrew S / Tetteh, Leticia F / Ramadan, Howida / Arnone, Gina / Li, Jiannong / Zhao, Xiuhua / Sharma, Ritin / Darville, Lancia N F / Fang, Bin / Smalley, Inna / Messina, Jane L / Koomen, John M / Sondak, Vernon K / Smalley, Keiran S M. ·Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida. · Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida. · Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia. · NYU Langone Medical Center, New York, New York. · Winship Cancer Institute of Emory University School of Medicine, Atlanta, Georgia. · Department of Tumor Biology, Moffitt Cancer Center, Tampa, Florida. · Department of Proteomics, Moffitt Cancer Center, Tampa, Florida. · Molecular Oncology, Moffitt Cancer Center, Tampa, Florida. · Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida. keiran.smalley@moffitt.org. ·Clin Cancer Res · Pubmed #29674508.

ABSTRACT:

2 Clinical Trial Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. 2015

Gibney, Geoffrey T / Kudchadkar, Ragini R / DeConti, Ronald C / Thebeau, Melissa S / Czupryn, Maria P / Tetteh, Leticia / Eysmans, Cabell / Richards, Allison / Schell, Michael J / Fisher, Kate J / Horak, Christine E / Inzunza, H David / Yu, Bin / Martinez, Alberto J / Younos, Ibrahim / Weber, Jeffrey S. ·Department of Cutaneous Oncology and Comprehensive Melanoma Research Center, Moffitt Cancer Center, Tampa, Florida. Department of Oncologic Sciences, University of South Florida, Tampa, Florida. geoffrey.gibney@moffitt.org. · Division of Oncology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia. · Department of Cutaneous Oncology and Comprehensive Melanoma Research Center, Moffitt Cancer Center, Tampa, Florida. Department of Oncologic Sciences, University of South Florida, Tampa, Florida. · Department of Cutaneous Oncology and Comprehensive Melanoma Research Center, Moffitt Cancer Center, Tampa, Florida. · Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida. · Bristol-Myers Squibb, Early Clinical and Translational Research, Princeton, New Jersey. · Department of Clinical Pharmacology, College of Medicine, Minufiya University, Minufiya, Egypt. Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman. ·Clin Cancer Res · Pubmed #25524312.

ABSTRACT: PURPOSE: The anti-programmed death-1 (PD-1) antibody nivolumab (BMS-936558) has clinical activity in patients with metastatic melanoma. Nivolumab plus vaccine was investigated as adjuvant therapy in resected stage IIIC and IV melanoma patients. EXPERIMENTAL DESIGN: HLA-A*0201 positive patients with HMB-45, NY-ESO-1, and/or MART-1 positive resected tumors received nivolumab (1 mg/kg, 3 mg/kg, or 10 mg/kg i.v.) with a multi-peptide vaccine (gp100, MART-1, and NY-ESO-1 with Montanide ISA 51 VG) every 2 weeks for 12 doses followed by nivolumab maintenance every 12 weeks for 8 doses. Primary objective was safety and determination of a maximum tolerated dose (MTD). Secondary objectives included relapse-free survival (RFS), overall survival (OS), and immunologic correlative studies. RESULTS: Thirty-three patients were enrolled. Median age was 47 years; 55% were male. Two patients had stage IIIC disease; 31 patients had stage IV disease. Median follow-up was 32.1 months. MTD was not reached. Most common related adverse events (>40%) were vaccine injection site reaction, fatigue, rash, pruritus, nausea, and arthralgias. Five related grade 3 adverse events [hypokalemia (1), rash (1), enteritis (1), and colitis (2)] were observed. Ten of 33 patients relapsed. Estimated median RFS was 47.1 months; median OS was not reached. Increases in CTLA-4(+)/CD4(+), CD25(+)Treg/CD4(+), and tetramer specific CD8(+) T-cell populations were observed with treatment (P < 0.05). Trends for lower baseline myeloid-derived suppressor cell and CD25(+)Treg/CD4(+) populations were seen in nonrelapsing patients; PD-L1 tumor status was not significantly associated with RFS. CONCLUSIONS: Nivolumab with vaccine is well tolerated as adjuvant therapy and demonstrates immunologic activity with promising survival in high-risk resected melanoma, justifying further study.